International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants

Last updated: February 7, 2024
Sponsor: Stéphane Zuily
Overall Status: Active - Recruiting

Phase

N/A

Condition

Antiphospholipid Syndrome

Thrombosis

Platelet Disorders

Treatment

Rivaroxaban

Clinical Study ID

NCT04262492
2019-A01415-52
  • All Genders

Study Summary

This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient receiving a comprehensive information about the study, and not opposed toparticipate
  • Age ≥ 18 yo
  • Classification of definite APS according to revised Sapporo-Sydney criteria
  • Direct oral anticoagulant treatment prescribed during at least 6 months or with thepossibility of follow-up of at least 6 months

Exclusion

Exclusion Criteria:

  • Incomplete revised Sapporo-Sydney criteria
  • No data regarding the recurrent thrombosis
  • Pregnant woman
  • Age < 18 yo

Study Design

Total Participants: 500
Treatment Group(s): 1
Primary Treatment: Rivaroxaban
Phase:
Study Start date:
October 21, 2020
Estimated Completion Date:
April 30, 2030

Connect with a study center

  • Stéphane Zuily

    Nancy, 54500
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.